News
Futurism on MSN3d
This Sleazy GLP-1 Prescription Site Is Using Deepfaked "Before-and-After" Photos of Fake Patients, and Running Ads Showing AI-Generated Ozempic BoxesMEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...
How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...
From Novo Nordisk to UnitedHealth, onetime chief executives are returning to guide their former organizations in times of ...
Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...
Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.
Barchart on MSN14h
Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...
Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facility for ...
Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...
Interesting Engineering on MSN5d
Molecular fingerprints redefine insulin resistance, shake up diabetes treatmentScientists discover unique insulin responses in each person, opening new paths for early diabetes detection and treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback